PRF Technologies Ltd. (PRFX): Capital Expenditures
$2.0K
Year ended 2025-12-31
-30.7%
3-year compound annual growth
-27.5%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.0K | -84.6% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $13.0K | +44.4% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $9.0K | +50.0% | 2026-03-26, From 2023-01-01 |
| 2022-12-31 | $6.0K | -88.0% | 2025-04-07, From 2022-01-01 |
| 2021-12-31 | $50.0K | +400.0% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $10.0K | n/a | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | $0 | n/a | 2022-03-16, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $2.0K | -84.6% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $18.0K | n/a |
| Skinvisible, Inc. (SKVI) | 2025-12-31 | $4.1K | -55.7% |
| Talphera, Inc. (TLPH) | 2024-12-31 | $0 | -100.0% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $780.0K | +68.1% |
| Genelux Corp (GNLX) | 2025-12-31 | $1.10M | +188.2% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $500.0K | n/a |
| Altimmune, Inc. (ALT) | 2025-12-31 | $11.0K | n/a |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $0 | -100.0% |
Compare PRFX, BDPT, SKVI, TLPH side by side · Screen every company in Pharmaceutical Preparations ↗